Thomas F Whayne

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. doi Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Am J Cardiovasc Drugs 16:83-92. 2016
  2. ncbi Unique Coronary Artery Disease Differences in Women as Related to Revascularization
    Thomas F Whayne
    326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200, USA
    Curr Med Chem 22:3597-606. 2015
  3. ncbi Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
    Thomas F Whayne
    Gill Heart Institute, 326 Wethington Building, 900 South Limestone Street, Lexington KY 40356 0200, USA
    Curr Vasc Pharmacol 13:637-48. 2015
  4. doi Cardiovascular medicine at high altitude
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Angiology 65:459-72. 2014
  5. doi Epigenetics in the development, modification, and prevention of cardiovascular disease
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Mol Biol Rep 42:765-76. 2015
  6. ncbi Medications not intended for treatment of dyslipidemias and with a variable effect on lipids
    Thomas F Whayne
    326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200
    Curr Pharm Des 20:6325-38. 2014
  7. doi Ischemic heart disease and the Mediterranean diet
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Curr Cardiol Rep 16:491. 2014
  8. doi Assessment of low-density lipoprotein targets
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Angiology 64:411-6. 2013
  9. ncbi Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH Trial
    Thomas F Whayne
    Divisions of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Hematol Agents Med Chem 9:269-76. 2011
  10. doi Nutrition and the healthy heart with an exercise boost
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, 40536 0200, USA
    Can J Physiol Pharmacol 90:967-76. 2012

Collaborators

Detail Information

Publications26

  1. doi Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Am J Cardiovasc Drugs 16:83-92. 2016
    ..There is every reasonable hope for significant cardiovascular benefit from these new additions to our medical cardiovascular armamentarium. ..
  2. ncbi Unique Coronary Artery Disease Differences in Women as Related to Revascularization
    Thomas F Whayne
    326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200, USA
    Curr Med Chem 22:3597-606. 2015
    ....
  3. ncbi Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
    Thomas F Whayne
    Gill Heart Institute, 326 Wethington Building, 900 South Limestone Street, Lexington KY 40356 0200, USA
    Curr Vasc Pharmacol 13:637-48. 2015
    ..The bottom line on coffee, for those who enjoy the brew, is that it is a wonderful beverage with rare associated CV disadvantage and with much to recommend it from an overall CV standpoint. ..
  4. doi Cardiovascular medicine at high altitude
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Angiology 65:459-72. 2014
    ..The CMS includes extreme polycythemia, severe RVH, excess pulmonary hypertension, low systemic BP, arterial oxygen desaturation, and hypoventilation...
  5. doi Epigenetics in the development, modification, and prevention of cardiovascular disease
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Mol Biol Rep 42:765-76. 2015
    ..Aging itself may be altered by epigenetic modification. Knowledge of epigenetics and its relevance to the development, modification, and prevention of CV disease is in a very preliminary stage but has an infinite future. ..
  6. ncbi Medications not intended for treatment of dyslipidemias and with a variable effect on lipids
    Thomas F Whayne
    326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200
    Curr Pharm Des 20:6325-38. 2014
    ..Mention is also made of lipid lowering effects of medications intended for other purposes (e.g. angiotensin receptor blockers and orlistat). ..
  7. doi Ischemic heart disease and the Mediterranean diet
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Curr Cardiol Rep 16:491. 2014
    ..Benefit also extends to other noncommunicable diseases with a decrease in cancer, Parkinson's disease, and Alzheimer's disease. Further quantitation of benefit and understanding of mechanisms involved in dietary benefit is essential...
  8. doi Assessment of low-density lipoprotein targets
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Angiology 64:411-6. 2013
    ..A strategy of LDL-C reduction in no way interferes with increased understanding of the complexities of atherosclerosis and new approaches to CV disease prevention as they become supported by outcomes studies...
  9. ncbi Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH Trial
    Thomas F Whayne
    Divisions of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Hematol Agents Med Chem 9:269-76. 2011
    ..Continued collaboration between cardiologists concentrating on medical approaches with interventionists and cardiac surgeons (heart team approach) is essential for optimal management for each individual patient. ..
  10. doi Nutrition and the healthy heart with an exercise boost
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, 40536 0200, USA
    Can J Physiol Pharmacol 90:967-76. 2012
    ..Antioxidants, endogenous or exogenous, have received increased interest and appear to play a favorable nutritional role. CV health starts with good nutrition...
  11. doi Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Lexington, 40536, USA
    Angiology 62:415-21. 2011
    ..The occurrence of the most serious complication of myopathy-rhabdomyolysis-is very rare, but awareness of the problem, risks, and prevention are essential...
  12. doi [Problems with statins and the marketing of these medications]
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Rev Med Chil 138:511-4. 2010
    ..This actually occurs with any statin, a decrease also enhanced by ezetimibe. Statins have benefited the lives of our patients but, as with any treatment, the physician needs to look critically at all the problems and claims made...
  13. doi What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Ther 28:106-23. 2010
    ..The result is that a number of these alternative medications will then interact with conventional CV medications, many times unfavorably...
  14. doi High-density lipoprotein cholesterol: current perspective for clinicians
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536, USA
    Angiology 60:644-9. 2009
    ..High-density lipoprotein cholesterol may play an important role in improving cardiovascular risk in the 60% of patients who do not receive cardiovascular mortality/morbidity benefit from low-density lipoproteins reduction by statins...
  15. ncbi Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population
    Thomas F Whayne
    Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, 326 Wethington Building, 900 South Limestone, Lexington, KY 40536 0200, USA
    Indian Heart J 59:218-25. 2007
    ..Future treatments undoubtedly will involve genetics, but for now, aggressive medication use can favorably modify risk although not eliminate it...
  16. ncbi Problems with the new Adult Treatment Panel III guidelines
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Division of Cardiovascular Medicine, Lexington, KY 40536 0284, USA
    Prev Cardiol 5:91. 2002
  17. ncbi Current evidence for antithrombotic therapy after peripheral vascular interventions
    Sibu P Saha
    Division of Cardiothoracic Surgery, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
    Curr Vasc Pharmacol 11:507-13. 2013
    ..Available medications remain in a state of flux and new oral direct thrombin and Factor Xa inhibitors may also find a place as clinical evidence-based medicine accumulates. ..
  18. ncbi Synopsis of an epidemiologic study of a Kentucky county in the Coronary Valley
    Vivian M Abascal
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone, Lexington, KY 40536 0200, USA
    J Ky Med Assoc 106:527-31. 2008
    ..These findings may explain the high prevalence of cardiovascular (CV) disease in general and coronary heart disease (CHD) in particular, in parts of rural Appalachia even without the presence of significantly elevated cholesterol levels...
  19. pmc Evidence-based management of carotid artery disease
    Sibu P Saha
    Gill Heart Institute and the Divisions of Cardiothoracic Surgery and Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA
    Int J Angiol 19:e21-4. 2010
    ..A medical-surgical team approach is now greatly contributing to the avoidance of stroke and its devastation...
  20. ncbi Cardiovascular care: a challenge for Kentucky
    Sibu P Saha
    Gill Heart Institute, 326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200, USA
    J Ky Med Assoc 107:295-7. 2009
    ..Treating CV disease is clearly not enough; lifestyle habits need to be changed before CV disease develops...
  21. ncbi Current management of peripheral vascular disease: where is the evidence?
    Sibu P Saha
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Cardiovasc Hematol Agents Med Chem 9:128-36. 2011
    ..It has been shown that these patients are undertreated in spite of their high cardiovascular risk. It is mandatory that they receive the same intensive treatment of risk factors as that given to coronary heart disease patients...
  22. doi Women, the menopause, hormone replacement therapy and coronary heart disease
    Thomas F Whayne
    aDivision of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky bDivision of Cardiovascular Medicine, Texas Tech University HSC, and Paul Foster School of Medicine, El Paso, Texas, USA
    Curr Opin Cardiol 30:432-8. 2015
    ..Despite a misconception that women have a minimal risk for coronary heart disease (CHD), it is the major cause of female deaths. This review highlights issues of hormone replacement therapy (HRT) and CHD in women...
  23. doi Thioredoxins in cardiovascular disease
    Thomas F Whayne
    a Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200, USA
    Can J Physiol Pharmacol 93:903-11. 2015
    ..Diabetes mellitus has a major association with CVDs; increase in Trx levels may reflect insulin resistance. Identification of Trx system abnormalities may lead to innovative approaches to treat multiple CVDs and other pathologies. ..
  24. doi Coenzyme Q-10 in Human Health: Supporting Evidence?
    Sibu P Saha
    From the Division of Cardiothoracic Surgery and the Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington
    South Med J 109:17-21. 2016
    ..This review is an attempt to actualize the available information on CoQ10 and define its potential benefit and appropriate usage. ..
  25. doi Current treatment of heart failure in the USA
    Charles R Salters
    The University of Kentucky, 740 South Limestone Street, J525 Kentucky Clinic, Lexington, KY 40536 0284, USA
    Expert Rev Cardiovasc Ther 8:279-90. 2010
    ..It is the aim of this review to describe the framework for approaching heart failure patients so that the physician can provide the most appropriate therapies at each stage of the disease...
  26. doi Nonprescription statins: not ready for prime time
    Thomas F Whayne
    Am J Cardiol 101:745-6; author reply 746. 2008